BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Pathology from the Atomic Scale on Up
DTSTART:20210930T121500
DTEND:20210930T133000
DTSTAMP:20260413T204153Z
UID:be43774411e89117e55bb1f83aef12a7a7c6a414d53347449565a740
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Garry NOLAN Professor\, Microbiology & Immunology - Baxt
 er Laboratory Member\, Bio-X Member\, Child Health Research Institute Memb
 er\, Stanford Cancer Institute Stanford University - CA\, USA\nA Lola and 
 John Grace Distinguished Lecture in Cancer Research\n\nThis seminar will a
 lso be televised to CHUV Visioconférence 2 + Biopôle B301/CLE + Geneva U
 niversity-CMU Auditorium Paul Boymond B02.226\n\nDr. Nolan is the Rachford
  and Carlota A. Harris Professor in the Department of Microbiology and Imm
 unology at Stanford University School of Medicine. He trained with Leonard
  Herzenberg (for his Ph.D.) and Nobelist Dr. David Baltimore (for postdoct
 oral work for the first cloning/characterization of NF-κB p65/ RelA and t
 he development of rapid retroviral production systems). He has published o
 ver 300 research articles and is the holder of 20 US patents\, and has bee
 n honored as one of the top 25 inventors at Stanford University.\n\nDr. No
 lan is the first recipient of the Teal Innovator Award (2012) from the Dep
 artment of Defense (a $3.3 million grant for advanced studies in ovarian c
 ancer)\, the first recipient of an FDA BAAA\, for “Bio-agent protection
 ” grant\, $3million\, from the FDA for a “Cross-Species Immune System 
 Reference”\, and received the award for “Outstanding Research Achievem
 ent in 2011” from the Nature Publishing Group for his development of CyT
 OF applications in the immune system. Dr. Nolan has new efforts in the stu
 dy of Ebola\, having developed instrument platforms to deploy in the field
  in Africa to study Ebola samples safely with the need to transport them t
 o overseas labs (funded by a new $3.5 million grant from the FDA) and anot
 her grant to study the effects of Zika virus on humans (also from the FDA)
 .\n\nDr. Nolan is an outspoken proponent of translating public investment 
 in basic research to serve the public welfare. Dr. Nolan was the founder o
 f Rigel Inc. (NASDAQ: RIGL)\, and Nodality\, Inc. (a diagnostics developme
 nt company)\, BINA (a genomics computational infrastructure company sold t
 o Roche Diagnostics)\, Founder of Apprise (sold to Roche Sequencing Soluti
 ons)\, co-Founder of Ionpath\, co-Founder of Akoya\, and serves on the Boa
 rds of Directors of several companies as well as consults for other biotec
 hnology companies. DVS Sciences\, on which he was Chair of the Scientific 
 Advisory Board\, recently sold to Fluidigm for $207 million dollars (2014)
  on an investment of $14 million. Dr. Nolan is a member of the Parker Inst
 itute for Cancer Immunotherapy at Stanford.\n\nHis areas of research inclu
 de hematopoiesis\, cancer and leukemia\, autoimmunity and inflammation\, a
 nd computational approaches for network and systems immunology. Dr. Nolan
 ’s recent efforts are focused on a single cell analysis advance using a 
 mass spectrometry-flow cytometry hybrid device\, the so- call “CyTOF” 
 and the “Multiparameter Ion Beam Imager” (MIBI) developed by Dr. Mike 
 Angelo in his lab (Dr. Angelo is now an Assistant Professor in the Dept of
  Pathology at Stanford). The approaches use an advanced ion plasma source 
 to determine the levels of tagged reagents bound to cells—enabling a vas
 t increase in the number of parameters that can be measured per cell—eit
 her as flow cytometry devices (CyTOF) or imaging platforms for cancer (MIB
 I). Further efforts with another imaging platform termed CODEX (Akoya\, In
 c.) that inexpensively converts fluorescence scopes to high dimensional im
 aging platforms.\n\nDr. Nolan’s efforts are to enable a deeper understan
 ding not only of normal immune function\, trauma\, pathogen infection\, an
 d other inflammatory events but also detailed substructures of leukemias a
 nd solid cancers—which will enable wholly new understandings that will e
 nable better management of disease and clinical outcomes
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR